





PD-L1 Polyclonal Antibody

Catalog Number PA5-28115 Product data sheet

Details		Species Reactivity	
Size	100 µL	Species reactivity	Human
Host/Isotope	Rabbit / IgG	Published species	Human, Not Applicable
Class	Polyclonal	Tested Applications	Dilution *
Туре	Antibody	Immunohistochemistry (Frozen) (IHC (F))	Assay-dependent
Immunogen	Synthetic peptide corresponding to a region within amino acids 230 and 290 of CD274	Immunohistochemistry (Paraffin) (IHC (P))	1:100-1:1,000
Conjugate	Unconjugated	Western Blot (WB)	1:500-1:3,000
Form	Liquid	Immunocytochemistry (ICC/IF)	1:100-1:1,000
Concentration	0.97 mg/mL	Published Applications	
Purification	Antigen affinity chromatography	Western Blot (WB)	See 3 publications below
Storage buffer	PBS, pH 7, with 20% glycerol	Immunohistochemistry (IHC)	See 3 publications below
Contains	0.025% ProClin 300	Flow Cytometry (Flow)	See 1 publications below
Storage Conditions	Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.	* Suggested working dilutions are given as a guide only. It is recome experiment using appropriate negative and positive controls.	mended that the user titrate the product for use in their own

Product specific information

Recommended positive controls: A431, MDA-MB-231, MDA-MB-231 (24 µg/mL Tunicamycin treatment for 16 hr), MDA-MB-231, A549 (100 ng/mL IFN-gamma treatment for 48 hr), A431 (100 ng/mL IFN-gamma treatment for 48 hr). Store product as a concentrated solution. Centrifuge briefly prior to opening the vial.

Background/Target Information

Programmed death receptor ligand 1 (PD-L1, also called B7-H1) is a recently described B7 family member. To date, one specific receptor has been identified that can be ligated by PD-L1. This receptor, programmed death receptor 1 (PD-1), has been shown to negatively regulate T-cell receptor (TCR) signaling. Upon ligating its receptor, PD-L1 has been reported to decrease TCR-mediated proliferation and cytokine production. PD-L1 expression was found to be abundant on many murine and human cancers and could be further up-regulated upon IFN-gamma stimulation. Thus, PD-L1 might play an important role in tumor immune evasion.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.


For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization

Products are warranted to operate or perform substantially in conformance with published Product specifications in effect at the time of sale, as set forth in the Production documentation, specifications and/or accompanying package inserts ("Documentation"). No claim of suitability for use in applications regulated by FDA is made. The warranty provided herein is valid only when used by properly trained individuals. Unless otherwise stated in the Documentation, this warranty is limited to one year from date of shipment when the Product is subjected to normal, proper and intended usage. This warranty does not extend to anyone other than the Buyer. Any model or sample furnished to Buyer is merely illustrative of the general type and quality of goods and does not represent that any Product will conform to such model or sample.

NO OTHER WARRANTIES, EXPRESS OR IMPLED, ARE GRANTED INCLUDING WITHOUT LIMITATION, IMPLED WARRANTIES OF MERCHANTABILITY, FITNESS FOR ANY PARTICULAR PURPOSE, OR NON INFRINGEMENT, BUYER'S EXCLUSINE REALED FOR ROCKETOR POR REFUND FOR PORTOR PORT OF REFUND FOR PORTOR PORTO




Product Images For PD-L1 Polyclonal Antibody




PD-L1 Antibody (PA5-28115) in ICC/IF

Immunocytochemistry-Immunofluorescence analysis of PD-L1 was performed in MDA-MB-231 (left) and HeLa (right) cells fixed in ice-cold MeOH for 5 min. Green: PD-L1 Polyclonal Antibody (Product # PA5-28115) diluted at 1:500. Blue: Hoechst 33342 staining. Scale bar = 10 µm.




PD-L1 Antibody (PA5-28115)

Antibody specificity was demonstrated by shRNA mediated knockdown of the target protein. A431 cells were transfected with PD-L1 shRNA and decrease in signal intensity was observed in western blot application using PD-L1 antibody (Product # PA5-28115). {KD}



PD-L1 Antibody (PA5-28115) in IHC (P)

PD-L1 Polyclonal Antibody detects PD-L1 protein at cell membrane by immunohistochemical analysis. Sample: Paraffin-embedded human ovarian cancer. PD-L1 stained by PD-L1 Polyclonal Antibody (Product # PA5-28115) diluted at 1:4,000. Antigen Retrieval: Citrate buffer, pH 6.0, 15 min.



PD-L1 Antibody (PA5-28115) in IHC (P)


Immunohistochemistry (Paraffin) analysis of PD-L1 was performed in paraffin-embedded human ovarian carcinoma tissue using PD-L1 Polyclonal Antibody (Product # PA5-28115) at a dilution of 1:1000.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.

Products are warranted to operate or perform substantially in conformance with published Product specifications in effect at the time of sale, as set forth in the Production documentation, specifications and/or accompanying package insents ("Documentation"). No claim of suitability for use in applications regulated by FDA is made. The varranty provided herein is valid only when used by properly trained individuals. Unless otherwise stated in the Documentation, this warranty is limited to one year from date of shipment when the Product is subjected to normal, proper and intended usage. This warranty does not extend to anyone other than the Buyer. Any model or sample


NO OTHER WARRANTIES, EXPRESS OR MINELD, ARE GRANTED INCLUDING WITHOUT LIMITATION, IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR ANY PARTICULAR PURPOSE, OR NON INFRINGEMENT. BUYER'S EXCLUSIVE REMEDY FOR NON-CONFORMING PRODUCTS DURING THE WARRANTY PERIOD IS LIMITED TO REPRIA, PERIOLACEMENT OF OR REFUND FOR THE NON-CONFORMING PRODUCTS DATE IN ADMINISTER, OR WITHOUT OF THE PROPAGE AND THE PROPAGE OR THE PURPOR OF REPRODUCTS AS THE RESULT OF (I) ACCIDENT OF FORCE MALEYER, (II) MISSISSE, FAULT OR NEGLECON TO THE PROPAGE OR REPUND FOR PRODUCTS AS THE RESULT OF (I) ACCIDENT OF FORCE MALEYER, (III) MISSISSE, FAULT OR NEGLECON TO THE PROPERTY OF THE PROPAGE OR REPUND FOR THE PROPAGE AS THE PROPAGE OR THE PR






PD-L1 Antibody (PA5-28115) in WB

Western Blot analysis of PD-L1 was performed by separating 30 µg of non-transfected (–) and transfected (+) 293T whole cell extracts by 10% SDS-PAGE. Proteins were transferred to a membrane and probed with a PD-L1 Polyclonal Antibody (Product # PA5-28115) at a dilution of 1:1000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody., and the signal was developed with Trident ECL plus-Enhanced




PD-L1 Antibody (PA5-28115) in WB

Western Blot analysis of PD-L1 was performed by separating 30 µg of untreated (–) and treated (+) MDA-MB-231 whole cell extracts by 10% SDS-PAGE. Proteins were transferred to a membrane and probed with a PD-L1 Polyclonal Antibody (Product # PA5-28115) at a dilution of 1:1000.



PD-L1 Antibody (PA5-28115) in WB

Western Blot analysis of PD-L1 was performed by separating 30 µg of untreated (–) and treated (+) A549 whole cell extracts by 10% SDS-PAGE. Proteins were transferred to a membrane and probed with a PD-L1 Polyclonal Antibody (Product # PA5-28115) at a dilution of 1:500.



PD-L1 Antibody (PA5-28115) in WB


Western Blot analysis of PD-L1 was performed by separating 30 µg of untreated (–) and treated (+) A431 whole cell extracts by 10% SDS-PAGE. Proteins were transferred to a membrane and probed with a PD-L1 Polyclonal Antibody (Product # PA5-28115) at a dilution of 1:500.

or Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization

Products are warranted to operate or perform substantially in conformance with published Product specifications in effect at the time of sale, as set forth in the Production documentation, specifications and/or accompanying package inserts ("Documentation"). No claim of suitability for use in applications regulated by FDA is made. The warranty provided herein is valid only when used by properly trained individuals. Unless otherwise stated in the Documentation, this warranty is limited to one year from date of shipment when the Product is subjected to normal, proper and intended usage. This warranty does not extend to anyone other than the Buyer. Any model or sample


NO OTHER WARRANTIES, EXPRESS OR IMPLED, ARE GRANTED INCLUDING WITHOUT LIMITATION, IMPLED WARRANTIES OF MERCHANTABILITY, FITNESS FOR ANY PARTICULAR PURPOSE, OR NON INFRINGEMENT, BUYER'S EXCLUSIVE REACTOR FOR NOR-ON-OFFINIAM PRODUCTS DURING THE WARRANTY PERIOD IS LIMITED TO REPAIR, REPLACEMENT OF OR REFUND FOR OR REFUND FOR OR REFUND FOR OR REFUND FOR PRODUCTS. IN EAST THE REVOLUTION TO FROM REPLACE OR REFUND FOR PRODUCTS. AS THE RESULT OF (IN ACCIDENCE TO FOR REFUND FOR PRODUCTS IN A MANNER FOR WHICH THEY WERE NOT DESIGNED, OR (IN) MPROPER STORAGE AND HANDLING OF THE PRODUCTS. Unless otherwise expressly stated on the Product or in the documentation accompanying the Product, the Product is intended for research on your day is not to be used for any other purpose, including without limitation, unachidrized commercial uses, in vitto departs.





PD-L1 Antibody (PA5-28115) in WB

Western Blot using PD-L1 Polyclonal Antibody (Product # PA5-28115). Various whole cell extracts (30 µg) were separated by 10% SDS-PAGE, and the membrane was blotted with PD-L1 Polyclonal Antibody (Product # PA5-28115) diluted at 1:2,000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody.



PD-L1 Antibody (PA5-28115) in WB

Western Blot analysis of PD-L1 was performed by separating 30 μ g of various whole cell extracts by 10% SDS-PAGE. Proteins were transferred to a membrane and probed with a PD-L1 Polyclonal Antibody (Product # PA5-28115) at a dilution of 1:2000 and a HRP-conjugated anti-rabbit IgG secondary antibody.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization

Products are warranted to operate or perform substantially in conformance with published Product specifications in effect at the time of sale, as set forth in the Production documentation, specifications and/or accompanying package inserts ("Documentation"). No claim of suitability for use in applications regulated by FDA is made. The varranty provided herein is valid only when used by properly trained individuals. Unless otherwise stated in the Documentation, this warranty is limited to one year from date of shipment when the Product is subjected to normal, proper and intended usage. This warranty does not extend to anyone other than the Buyer. Any model or sample unstant of the product is subjected to normal, proper and intended usage. This warranty does not extend to anyone other than the Buyer. Any model or sample unstant of the product is subjected to normal, proper and intended usage. This warranty does not extend to anyone other than the Buyer. Any model or sample.

NO OTHER WARRANTIES, EXPRESS OR IMPLED, ARE GRANTED INCLUDING WITHOUT LIMITATION, IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR ANY PARTICULAR PURPOSE, OR NON INFRINGEMENT. BLYER'S EXCLUSIVE REMEDY FOR NON-CONFORMING PRODUCTS DURING NETHER WARRANTY FERIOD IS IMPRED TO REPRIA, BEFLACEMENT OF OR REFUND FOR OR REFUND FOR PRODUCTS. AS THE RESULT OF (I) ACCIDENT OF FORCE MAJEURE, (I) MISUSE, (II) MISUSE, (III) MISUSE, (III)



3 Western Blot Referen	ces
Species / Dilution	Summary
opeoles, Blidholl	PA5-28115 was used in Western Blotting to investigate the interaction between the HDAC6 inhibitor, A452, and immunomodulatory drugs on dexamethasone-sensitive and -resistant multiple myeloma cells compared with the current clinically tested HDAC6 inhibitor, ACY-1215.
Human / 1:1000	International journal of oncology (2019; 55: 499) "HDAC6selective inhibitor synergistically enhances the anticancer activity of immunomodulatory drugs in multiple myeloma." Author(s):Won HR,Lee DH,Yeon SK,Ryu HW,Kim GW,Kwon SH PubMed Article URL:http://dx.doi.org/10.3892/ijo.2019.4828
Human / Not Cited	PA5-28115 was used in Western Blotting to establish MLLT6 as a regulator of oncogenic and interferonassociated immune resistance.
	EMBO reports (2020; 21:) "MLLT6 maintains PD-L1 expression and mediates tumor immune resistance." Author(s):Sreevalsan S,Döring M,Paszkowski-Rogacz M,Brux M,Blanck C,Meyer M,Momburg F,Buchholz F,Theis M PubMed Article URL:http://dx.doi.org/10.15252/embr.202050155
	PA5-28115 was used in Western Blotting to suggest that a therapeutic strategy that combines ACY-1215 and oxaliplatin warrants attention for the treatment of solid tumors, including CRC.
Human / 1:1000	International journal of oncology (2018; 53: 844) "The HDAC6 inhibitor ACY1215 enhances the anticancer activity of oxaliplatin in colorectal cancer cells." Author(s):Lee DH,Won HR,Ryu HW,Han JM,Kwon SH PubMed Article URL:http://dx.doi.org/10.3892/ijo.2018.4405
3 Immunohistochemist	ry References
Species / Dilution	Summary
Human / 1:7500	PA5-28115 was used in Immunohistochemistry to identify if CD4+ and CD8+ T cells are potential culprits of checkpoint inhibitor-associated immune encephalitis.
	Nature medicine (2019; 25: 1243) "A case report of clonal EBV-like memory CD4 ⁺ T cell activation in fatal checkpoint inhibitor-induced encephalitis." Author(s):Johnson DB,McDonnell WJ,Gonzalez-Ericsson PI,Al-Rohil RN,Mobley BC,Salem JE,Wang DY,Sanchez V, Wang Y,Chastain CA,Barker K,Liang Y,Warren S,Beechem JM,Menzies AM,Tio M,Long GV,Cohen JV,Guidon AC,O'Hai M,Chandra S,Chowdhary A,Lebrun-Vignes B,Goldinger SM,Rushing EJ,Buchbinder EI,Mallal SA,Shi C,Xu Y,Moslehi JJ, Sanders ME,Sosman JA,Balko JM PubMed Article URL:http://dx.doi.org/10.1038/s41591-019-0523-2
Human / Not Cited	PA5-28115 was used in Immunohistochemistry to report a case of acute lung injury in a lung cancer patient initially treated for ICI-pneumonitis and later found to have concurrent SARS-CoV-2 infection.
	medRxiv: the preprint server for health sciences (2020;:) "Rapidly fatal pneumonitis from immunotherapy and concurrent SARS-CoV-2 infection in a patient with newly diagnosed lung cancer." Author(s):Lovly CM,Boyd KL,Gonzalez-Ericsson PI,Lowe CL,Brown HM,Hoffman RD,Sterling BC,Kapp ME,Johnson DB, Kopparapu PR,Iams WT,Warren MA,Noto MJ,Rini BI,Jagasia M,Das SR,Balko JM PubMed Article URL:http://dx.doi.org/10.1101/2020.04.29.20085738
	PA5-28115 was used in Immunohistochemistry to conclude that PD-L1, CD8, and CD20 are considered as early predicted and tracking markers for breast cancer.
Human / 1:100	Heliyon (2022; 8:) "Evaluation PD-L1, CD8 and CD20 as early predictor and tracking markers for breast cancer (BC) in Egypt." Author(s):Hamed MM,Gouida MS,Abd El-Aziz SR,El-Sokkary AMA PubMed Article URL:http://dx.doi.org/10.1016/j.heliyon.2022.e09474
1 Flow Cytometry Refe	rences
Species / Dilution	Summary
	PA5-28115 was used in Flow cytometry/Cell sorting to develop a novel protocol combining two platforms (IsoFluxTM and ImageStream®X) to improve circulating tumour cells evaluation.
Human / 1:100	Cancers (2021; 13:) "Deep Phenotypic Characterisation of CTCs by Combination of Microfluidic Isolation (IsoFlux) and Imaging Flow Cytometry (ImageStream)." Author(s):Ruiz-Rodríguez AJ,Molina-Vallejo MP,Aznar-Peralta I,González Puga C,Cañas García I,González E,Lorente J. Serrano MJ,Garrido-Navas MC PubMed Article URL:http://dx.doi.org/10.3390/cancers13246386

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.

Products are warranted to operate or perform substantially in conformance with published Product specifications in effect at the time of sale, as set forth in the Production documentation, specifications and/or accompanying package inserts ("Documentation"). No claim of suitability for use in applications regulated by FDA is made. The warranty is provided herein is valid only when used by properly trained individuals. Unless otherwise stated in the Documentation, this warranty is limited to one year from date of shipment when the Product is subjected to normal, proper and intended usage. This warranty does not extend to anyone other than the Buyer. Any model or sample furnished to Buyer is merely illustrative of the general type and quality of goods and does not represent that any product will conform to such model or sample furnished to Buyer is merely illustrative of the general type and quality of goods and does not represent that any product will be conformed to the product is subjected to normal, proper and intended usage. This warranty does not extend to anyone other than the Buyer. Any model or sample furnished to Buyer is a subjected to normal, proper and intended usage. This warranty does not extend to anyone other than the Buyer. Any model or sample furnished to Buyer is a subjected to normal, proper and intended usage. This warranty does not extend to anyone other than the Buyer. Any model or sample furnished to Buyer is a subject to the product is subjected to normal, proper and intended usage. This warranty is subjected to normal, proper and intended usage. This warranty does not extend to anyone other than the Buyer. Any model or sample furnished to Buyer is a subject to the product is subjected to normal, proper and intended usage. This warranty is subjected to normal, proper and intended usage.

NO OTHER WARRANTIES, EXPRESS OR IMPLED, ARE GRANTED INCLUDING WITHOUT LIMITATION, IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR ANY PARTICULAR PURPOSE, OR NON INFRINGEMENT. BUYER'S EXCLUSIVE REMEDY FOR NON-CONFORMING PRODUCTS DURING THE WARRANTY PERIOD IS LIMITED TO REPAIR, REPLACE OR REFUND FOR THE NON-CONFORMING PRODUCT(S) AT SELLER'S SOLE OPTION. THERE IS NO DELICATION TO REPAIR, REPLACE OR REFUND FOR PRODUCTS AS THE RESULT OF (I) ACCIDENT, DISASTER OR EVENT OF FORCE MAJEURE, (II) MISUSE, FALLT OR NEGLEGATION TO REPAIR, REPLACE OR REFUND FOR PRODUCTS IN A MANNER FOR WHICH THEY WERE NOT DESCRIBED, OR (IV) IMPROPER STORAGE AND HANDLING OF THE PRODUCTS. Unless otherwise expressly stated on the Product or in the documentation accompanying the Product, the Product is intended for research only and is not to be used for any other purpose, including without limitation, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses, or any type of consumption by or application to human or animals.



